公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2002 | P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection | JIN-TUNG LIANG ; KUO-CHIN HUANG ; Cheng Y.-M.; Hsu H.-C.; ANN-LII CHENG ; CHIH-HUNG HSU ; KUN-HUEI YEH ; Wang S.-M.; KING-JEN CHANG | International Journal of Cancer | 66 | 57 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
2012 | Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma | SHIH-HUNG YANG ; Lin L.-W.; YU-JEN FANG ; ANN-LII CHENG ; SUNG-HSIN KUO | Annals of Hematology | 6 | 2 | |
2006 | A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus | Pei Y.Y.; SUNG-HSIN KUO ; KUN-HUEI YEH ; Chuang S.-E.; CHIH-HUNG HSU ; Wen C.C.; Lin H.-I.; Gao M.; ANN-LII CHENG | Journal of Biological Chemistry | 43 | 39 | |
2021 | Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial | Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG ; Ducreux M. | The Lancet Oncology | 165 | 141 | |
2021 | Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial | Kudo M.; Lim H.Y.; ANN-LII CHENG ; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y. | Liver Cancer | 30 | 26 | |
2023 | Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial | Merle, Philippe; Kudo, Masatoshi; Edeline, Julien; Bouattour, Mohamed; ANN-LII CHENG ; Chan, Stephen L; Yau, Thomas; Garrido, Marcelo; Knox, Jennifer; Daniele, Bruno; Breder, Valeriy; Lim, Ho Yeong; Ogasawara, Sadahisa; Cattan, Stéphane; Chao, Yee; Siegel, Abby B; Martinez-Forero, Iván; Wei, Ziwen; Liu, Chih-Chin; Finn, Richard S | Liver cancer | 3 | 2 | |
2020 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial | Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG ; KEYnote-240 investigators | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 1188 | 1028 | |
2018 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trial | Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG ; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigators | The Lancet Oncology | 1744 | 1573 | |
2022 | Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial | Verset, Gontran; Borbath, Ivan; Karwal, Mark; Verslype, Chris; Van Vlierberghe, Hans; Kardosh, Adel; Zagonel, Vittorina; Stal, Per; Sarker, Debashis; Palmer, Daniel H; Vogel, Arndt; Edeline, Julien; Cattan, Stephane; Kudo, Masatoshi; ANN-LII CHENG ; Ogasawara, Sadahisa; Daniele, Bruno; Chan, Stephen L; Knox, Jennifer J; Qin, Shukui; Siegel, Abby B; Chisamore, Michael; Hatogai, Ken; Wang, Anran; Finn, Richard S; Zhu, Andrew X | Clinical cancer research : an official journal of the American Association for Cancer Research | 30 | 27 | |
2016 | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer | SHIH-HUNG YANG ; TING-CHUN KUO ; Wu H.; JHE-CYUAN GUO ; CHIUN HSU ; CHIH-HUNG HSU ; YU-WEN TIEN ; KUN-HUEI YEH ; ANN-LII CHENG ; SUNG-HSIN KUO | World Journal of Gastroenterology | 23 | 25 | |
2021 | Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study | Finn R.S.; Kudo M.; ANN-LII CHENG ; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J. | Clinical Cancer Research | 32 | 29 | |
2014 | A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors | Ghamande S.; CHIA-CHI LIN ; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; CHIH-HSIN YANG ; ANN-LII CHENG ; Ghalib M.H.; Chuadhary I.; Goel S. | Investigational New Drugs | 23 | 15 | |
2016 | A phase i clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment John T Kung | Liu K.-J.; Chao T.-Y.; Chang J.-Y.; ANN-LII CHENG ; Ch'Ang H.-J.; Kao W.-Y.; Wu Y.-C.; Yu W.-L.; Chung T.-R.; Whang-Peng J. | Journal of Biomedical Science | 19 | 16 | |
2001 | Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions | ANN-LII CHENG ; CHIH-HUNG HSU ; Lin J.-K.; Hsu M.-M.; YUNN-FANG HO ; She T.-S.; JENG-YUH KO ; Lin J.-T.; BOR-RU LIN ; MING-SHIANG WU ; Yu H.-S.; SHIOU-HWA JEE ; Chen G.-S.; Chen T.-M.; CHI-AN CHEN ; Lai M.-K.; YEONG-SHIAU PU ; MIN-HSIUNG PAN ; Wang Y.-J.; Tsai C.-C.; CHANG-YAO HSIEH | Anticancer Research | 1925 | 1695 | |
2006 | Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer | Ch'ang H.-J.; Wang C.-C.; ANN-LII CHENG ; CHIUN HSU ; YEN-SHEN LU ; MING-CHU CHANG ; Lin J.-T.; HSIU-PO WANG ; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 8 | 8 | |
2015 | Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients | Chang T.C.; Shiah H.S.; CHIH-HSIN YANG ; KUN-HUEI YEH ; ANN-LII CHENG ; Shen B.N.; Wang Y.W.; Yeh C.G.; Chiang N.J.; Chang J.Y.; Chen L.T. | Cancer Chemotherapy and Pharmacology | 87 | 74 | |
2020 | A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors | JIH-HSIANG LEE ; WEI-WU CHEN ; CHIH-HUNG HSU ; Yen Y.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; CHIA-CHI LIN | Investigational New Drugs | 38 | 36 | |
2018 | A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma | SHIH-HUNG YANG ; YU-YUN SHAO ; CHIA-CHI LIN ; SUNG-HSIN KUO ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 3 | 2 | |
2019 | Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors | Doi T.; CHIH-HSIN YANG ; Shitara K.; Naito Y.; ANN-LII CHENG ; Sarashina A.; Pronk L.C.; Takeuchi Y.; CHIA-CHI LIN | Targeted Oncology | 21 | 14 | |